undamentalytics Newsletter
Sign in

Onconetix, Inc. income statement

In fiscal 2025, Onconetix, Inc. reported revenue of $815,371, down 67.7% on the year before, operating income of −$17.9m (a -2190.0% margin) and net income of −$14.0m, or −$827.98 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0311
Cost of revenue1100
Gross profit−1111
Research and development20——
Selling, general and administrative151178
Operating income−36−56−18−16
Interest expense1110
Income before tax−37−60−14−10
Income tax−0−10—
Net income−37−59−14−10
Diluted EPS−$371653.79−$91167.36−$827.98—
Diluted shares (average)————
EBITDA−36−56−18−16

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRDF vs ONCOMNOV vs ONCOONCO vs STTK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Onconetix, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Onconetix, Inc.